IMMUPHARMA PLC — Remuneration Information 2017

Nov 24, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4907X

Immupharma PLC

24 November 2017

	24 NOVEMBER 2017

ImmuPharma PLC

("ImmuPharma" or the "Company")

Grant of Options

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 7,875,000 ordinary shares of 10p each in the Company ("Ordinary Shares") to certain of its Directors, non-executive Directors, employees and consultants representing 5.26% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis (the "Options"). 

The exercise price for the Options is 98.62 pence being the closing middle market share price on 23 November 2017.  The Options will vest subject to certain conditions after three years and are exercisable between three and ten years from the date of grant.

Options granted to Executive Directors and employees

Upon the recommendation of the Company's remuneration committee, the Company has granted 4,875,000 of the Options to the Company's Executive Directors and certain other employees pursuant to the Company's Share Option Plan which was adopted on 30 March 2017 (the "2017 Plan").  The amount of Options granted on 24 November 2017 to the Executive Directors is summarised in the following table:

Director	Ordinary Shares under Option
Dimitri Dimitriou	1,500,000
Robert Zimmer	1,875,000*

*includes 375,000 Options granted to Elisabeth Zimmer, Robert Zimmer's wife, who is also an employee of the Company.

Messrs Dimitriou and Zimmer currently have the following interests in issued Ordinary Shares:

Director	Number of Ordinary Shares	% of issued share capital at 24 November 2017
Dimitri Dimitriou	3,567,430	2.69
Robert Zimmer	25,344,514*	19.12

*includes 792,961 shares held by Elisabeth Zimmer, Robert Zimmer's wife, who is also an employee of the Company.

Following the grant of the options referred to above, Messrs Dimitriou and Zimmer will have the following interests in share options in the Company:

Director	Number of options	Exercise Price	Expiry Date
Dimitri Dimitriou	140,000 1,000,000 1,500,000	86.50p 50.25p 98.62p	04.02.2019 30.03.2027 24.11.2027
Robert Zimmer	200,000* 50,000* 100,000* 1,250,000* 1,875,000*	86.50p 90.75p 43.88p 50.25p 98.62p	04.02.2019 24.11.2021 02.06.2026 30.03.2027 24.11.2027

*includes options granted to Elisabeth Zimmer, Robert Zimmer's wife, who is also an employee of the Company

Following this grant of Options summarised above, the total number of share options outstanding pursuant to the 2017 Plan will be 8,125,000 representing 6.15% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.  2,005,000 Options remain outstanding pursuant to the Company's previous share option plan.  Together, there are 10,130,000 Options outstanding representing 7.64% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.

Options granted to Non-executive Directors

The Company has also granted certain Options to Non-executive Directors as summarised in the following table:

Director	Ordinary Shares under Option
Tim McCarthy	1,500,000
Franco di Muzio	300,000
Stephane Mery	300,000

Messrs McCarthy, di Muzio and Mery currently have the following interests in issued Ordinary Shares:

Director	Number of Ordinary Shares	% of issued share capital at 23 November 2017
Tim McCarthy	38,462	0.03%
Franco di Muzio	99,412	0.08%
Stephane Mery	21,490	0.02%

Following the grant of the Options referred to above, Messrs McCarthy, di Muzio and Mery will have the following interests in options over the Company's Ordinary Shares:

Director	Number of Ordinary Shares under Option	Exercise Price	Expiry Date
Tim McCarthy	500,000 1,000,000 1,500,000	43.88p 56.75p 98.62p	02.06.2026 12.07.2027 24.11.2027
Franco di Muzio	100,000 100,000 200,000 300,000	86.50p 43.88p 56.75p 98.62p	04.02.2019 02.06.2026 12.07.2027 24.11.2027
Stephane Mery	100,000 200,000 300,000	43.88p 56.75p 98.62p	02.06.2026 12.07.2027 24.11.2027

Total Share Options

As stated above, the total options outstanding under both the 2017 Plan and the Company's previous share option plan is 10,130,000, representing 7.64% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.  The total options outstanding that have been granted to non-employees and consultants is 5,185,000.  The total warrants outstanding is 153,850.  Taken altogether, there are currently 15,468,850 outstanding options and warrants, representing 11.67% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.

This announcement contains inside information for the purpose of Article 7 of Regulation (EU) 596/2014.

Ends

For further information, please contact:

ImmuPharma plc (www.immupharma.co.uk)
Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations Twitter: @immupharma	+44 (0) 20 7152 4080 +44 (0) 7721 413496
Northland Capital Partners Limited (NOMAD & Broker) Patrick Claridge, Corporate Finance David Hignell, Corporate Finance Jamie Spotswood, Corporate Finance Rob Rees, Corporate Broking	+44 (0) 20 3861 6625

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEBIBTTMBATBIR